Yelena Y. Janjigian, MD

Clinicians who are experienced with immunotherapy, like durvalumab, can easily identify and manage AEs associated with treatment for gastric/GEJ cancer.

Based on results from the MATTERHORN study of durvalumab/FLOT in gastric/GEJ cancers, the regimen should be considered a new SOC.

Yelena Y. Janjigian, MD, provides the background of the MATTERHORN trial, showcasing the importance of durvalumab plus FLOT in gastric/GEJ cancers.

Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.

Most adverse effects observed in combination therapies for gastric cancers are associated with chemotherapy, according to Yelena Y. Janjigian, MD.

Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.

Yelena Y. Janjigian, MD, spoke about which biomarkers were most predictive for treatment of localized gastric cancer.

Yelena Y. Janjigian, MD, spoke about using immunotherapy across settings to treat localized gastric cancer.

Yelena Y. Janjigian, MD, spoke about using immunotherapy to treat localized gastric cancer.